CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Rhea-AI Summary
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q4 2025 combined net revenues of $13.7M, up 31% year-over-year, and full-year 2025 net revenues of $44.5M, up 18% versus 2024. The company posted a $2.9M net loss for 2025 and $1.7M adjusted earnings. Total assets were $76.8M and shareholders' equity was $24.9M at year end.
Key developments: international launches/approvals, Talicia co-commercialization, permanent J-code for Caldolor, positive FIGHT DMD Phase II topline results and FDA fast track designation in early 2026.
Positive
- Net revenue +18% for full-year 2025 to $44.5M
- Q4 2025 revenue +31% to $13.7M
- Debt reduction of $10M on credit facility versus 2024
- Permanent J-code J1741 established for Caldolor (Dec 2025)
- Positive Phase II FIGHT DMD topline: high-dose ifetroban improved LVEF by 5.4% vs natural history
Negative
- Net loss of $2.9M for 2025 despite adjusted earnings improvement
- Operating expenses totaled $47.3M, exceeding net revenues
- Cash and equivalents of $11.4M may limit near-term flexibility
Key Figures
Market Reality Check
Peers on Argus
CPIX traded down 1.63% while key peers showed mixed performance (e.g., ASRT and CRDL up, DRRX and INCR down). Momentum scanner flagged only two peers moving up, diverging from CPIX’s direction, pointing to stock-specific drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Product launch | Positive | +4.6% | National U.S. sales promotion launch for Talicia under co-commercialization deal. |
| Feb 25 | Partnership update | Positive | +4.6% | Details on Talicia joint commercialization structure and Cumberland’s $4M investment. |
| Feb 24 | Earnings date | Neutral | +4.6% | Scheduled date and call for 2025 annual results and company update. |
| Feb 04 | Regulatory designation | Positive | +4.0% | FDA Fast Track designation for ifetroban in DMD heart disease program. |
| Dec 08 | Reimbursement update | Positive | -9.2% | Caldolor J-code J1741 linked to a reimbursement price for non-opioid pain management. |
Recent CPIX news has usually led to positive price reactions, with one notable selloff on otherwise favorable reimbursement news, suggesting occasional profit-taking or skepticism on good headlines.
Over the past several months, Cumberland has highlighted progress across its portfolio and pipeline. Talicia co-commercialization and U.S. launch news on Feb 25, 2026 and an earnings-date announcement the prior day each coincided with ~4.6% gains. The ifetroban DMD Fast Track designation on Feb 4, 2026 also saw a positive move. By contrast, a positive Caldolor J-code reimbursement update on Dec 8, 2025 was followed by a -9.21% decline, showing that good clinical or reimbursement news has not always translated into sustained strength.
Market Pulse Summary
This announcement highlights Cumberland’s 31% Q4 and 18% full‑year 2025 revenue growth, a swing to $1.7M in adjusted earnings, and stronger operating cash flow of $4.9M. It also underscores strategic moves: Talicia co-commercialization, Caldolor’s J-code reimbursement, and positive ifetroban DMD Phase II data with Fast Track designation. Investors may track revenue mix across Kristalose, Sancuso, Vibativ, Caldolor and Talicia, alongside expense control and further regulatory or clinical milestones to gauge ongoing execution.
Key Terms
j-code regulatory
cms reimbursement regulatory
qualified infectious disease product (qidp) regulatory
orphan drug regulatory
rare pediatric disease regulatory
fast track designation regulatory
phase ii medical
AI-generated analysis. Not financial advice.
Net revenues for the full year 2025 were
The net loss for 2025 was
"We are pleased with
2025 HIGHLIGHTS INCLUDE:
International Expansion
In February 2025,
In September 2025,
In October 2025,
Expanded Commercial Portfolio
In October 2025,
Through a co-commercialization agreement,
Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin, and is now recommended as a first-line therapy in the American College of Gastroenterology (ACG) clinical guidelines. Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.
CMS Establishes Reimbursement for Caldolor® Through Permanent J-Code
Caldolor® received a key reimbursement milestone with the establishment of its permanent J-code, J1741, in December 2025. The J-Code is now officially linked to a CMS reimbursement price. This designation enables healthcare providers to access a clearly defined and reimbursable pathway for Caldolor, supporting its continued adoption across hospital and clinical settings.
As the nation continues to address the opioid crisis, Caldolor offers an important non-opioid option for managing pain and fever. The availability of CMS reimbursement through J1741 enhances provider access to this therapy, supporting safer pain management strategies and helping reduce reliance on opioid medications.
This reimbursement milestone reinforces Caldolor's role as a clinically proven, non-opioid alternative and strengthens its position within hospital protocols and opioid-sparing treatment initiatives. It also supports broader access for patients while advancing efforts to improve outcomes and promote responsible pain management.
Clinical Top-Line Study Results
In early 2025,
The trial enrolled 41 DMD patients who received either low dose ifetroban (150 mg per day), high dose ifetroban (300 mg per day) or placebo. The study's primary endpoint was an improvement in the heart's left ventricular ejection fractions (LVEF). Key findings included:
- High dose ifetroban treatment resulted in an overall
3.3% improvement in LVEF. - The high dose ifetroban group showed an increase in
1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of1.5% . - When compared with propensity matched natural history controls, the difference was even more pronounced, with the high dose treatment providing a significant
5.4% overall improvement in LVEF, as the control patients experienced a3.6% decline in LVEF. - Both doses of ifetroban were well-tolerated, with no serious drug-related events.
The top-line FIGHT DMD study findings were selected for a late-breaking presentation at the Muscular Dystrophy Association's Clinical & Scientific Conference in March 2025 and they were presented at the Parent Project Muscular Dystrophy Annual Conference in June 2025.
FINANCIAL RESULTS:
Net Revenue: For 2025, net revenues were
Operating Expenses: Total operating expenses for 2025 were
Net Income (Loss): The net loss for 2025 was
Adjusted Earnings: Adjusted earnings for 2025 were
Balance Sheet: On December 31, 2025,
EARNINGS REPORT CALL:
A conference call will be held today, March 3, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results.
The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.
Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via
ABOUT CUMBERLAND PHARMACEUTICALS:
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
- Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis.
For more information on
About Acetadote® (acetylcysteine) Injection
Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in
About Caldolor® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever.
Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.
About Kristalose® (lactulose) Oral Solution
Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com.
About Sancuso® (granisetron) Transdermal System
Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.
About Vaprisol® (conivaptan hydrochloride) Injection
Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com.
About Vibativ® (telavancin) for Injection
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com.
About Talicia®
Talicia® is an FDA approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer. Talicia is listed as a first line option in the 2024 ACG Guideline for the treatment of H. pylori and features three key advantages: 1) high eradication rates - >
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements, which are subject to certain risks and reflect
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Consolidated Balance Sheets December 31, 2025 and 2024 (Unaudited) | ||||
2025 | 2024 | |||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $ 11,444,693 | $ 17,964,184 | ||
Accounts receivable, net | 16,944,780 | 11,701,466 | ||
Inventories, net | 6,225,518 | 3,999,995 | ||
Prepaid and other current assets | 2,445,276 | 2,786,513 | ||
Total current assets | 37,060,267 | 36,452,158 | ||
Non-current inventories | 9,253,090 | 11,005,499 | ||
Property and equipment, net | 264,724 | 277,365 | ||
Intangible assets, net | 14,027,921 | 17,973,449 | ||
Goodwill | 914,000 | 914,000 | ||
Operating lease right-of-use assets | 8,343,832 | 6,176,923 | ||
Investment in co-commercialization | 3,986,780 | — | ||
Other assets | 2,973,378 | 2,784,016 | ||
Total assets | $ 76,823,992 | $ 75,583,410 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Accounts payable | $ 18,567,546 | $ 13,914,266 | ||
Operating lease current liabilities | 467,774 | 356,508 | ||
Revolving line of credit - current | — | 5,100,000 | ||
Other investment liabilities | 5,074,504 | — | ||
Other current liabilities | 12,635,095 | 12,250,955 | ||
Total current liabilities | 36,744,919 | 31,621,729 | ||
Revolving line of credit - long term | 5,240,733 | 10,176,170 | ||
Operating lease non-current liabilities | 4,471,965 | 4,939,739 | ||
Other long-term liabilities | 5,822,153 | 6,299,795 | ||
Total liabilities | 52,279,770 | 53,037,433 | ||
Commitments and contingencies | ||||
Equity: | ||||
Shareholders' equity: | ||||
Common stock – no par value; 100,000,000 shares authorized; 14,956,627 | 51,684,381 | 46,821,425 | ||
Accumulated deficit | (26,804,059) | (23,967,931) | ||
Total shareholders' equity | 24,880,322 | 22,853,494 | ||
Noncontrolling interests | (336,100) | (307,517) | ||
Total equity | 24,544,222 | 22,545,977 | ||
Total liabilities and equity | $ 76,823,992 | $ 75,583,410 | ||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Consolidated Statements of Operations (Unaudited) | ||||||||
Three months ended December 31, | Years ended December 31, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Net revenues | $ 13,678,651 | $ 10,435,569 | $ 44,521,431 | $ 37,867,945 | ||||
Costs and expenses: | ||||||||
Cost of products sold | 2,241,344 | 1,976,473 | 6,667,207 | 6,585,972 | ||||
Selling and marketing | 6,208,695 | 4,222,554 | 19,098,153 | 17,023,023 | ||||
Research and development | 1,549,656 | 1,292,671 | 5,566,498 | 4,816,206 | ||||
General and administrative | 4,036,913 | 3,326,466 | 11,946,909 | 11,126,901 | ||||
Amortization and impairment | 1,013,245 | 1,459,444 | 4,034,657 | 4,748,252 | ||||
Total costs and expenses | 15,049,853 | 12,277,608 | 47,313,424 | 44,300,354 | ||||
Operating loss | (1,371,202) | (1,842,039) | (2,791,993) | (6,432,409) | ||||
Interest income | 91,967 | 106,667 | 476,748 | 334,444 | ||||
Equity in loss of investee | (13,220) | — | (13,220) | — | ||||
Other income - gain on insurance proceeds | — | — | — | 237,089 | ||||
Interest expense | (112,942) | (223,261) | (495,990) | (605,508) | ||||
Loss before income taxes | (1,405,397) | (1,958,633) | (2,824,455) | (6,466,384) | ||||
Income tax benefit (expense) | (23,245) | 56,996 | (40,256) | 22,669 | ||||
Net loss | (1,428,642) | (1,901,637) | (2,864,711) | (6,443,715) | ||||
Net (income) loss at subsidiary attributable to | 16,950 | (2,177) | 28,583 | (36,055) | ||||
Net loss attributable to common shareholders | $ (1,411,692) | $ (1,903,814) | $ (2,836,128) | $ (6,479,770) | ||||
Loss per share attributable to common | ||||||||
Basic | $ (0.09) | $ (0.14) | $ (0.19) | $ (0.46) | ||||
Diluted | (0.09) | (0.14) | (0.19) | (0.46) | ||||
Weighted-average common shares outstanding: | ||||||||
Basic | 14,956,627 | 13,971,228 | 14,954,619 | 14,060,272 | ||||
Diluted | 14,956,627 | 13,971,228 | 14,954,619 | 14,060,272 | ||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows Years ended December 31, 2025 and 2024 (Unaudited) | ||||
2025 | 2024 | |||
Cash flows from operating activities: | ||||
Net loss | $ (2,864,711) | $ (6,443,715) | ||
Adjustments to reconcile net loss to net cash flows provided by (used | ||||
Depreciation and amortization expense | 4,145,201 | 4,902,560 | ||
Amortization of operating lease right-of-use asset | 1,140,738 | 1,140,738 | ||
Loss on co-commercialization investment | 13,220 | — | ||
Disposal of assets | — | 2,691 | ||
Stock-based compensation | 408,320 | 301,895 | ||
Increase (decrease) in non-cash contingent consideration | 46,569 | (1,460,804) | ||
Increase in cash surrender value of life insurance policies over | (142,927) | (139,953) | ||
Noncash interest expense | 23,185 | 28,313 | ||
Life insurance proceeds | — | (237,089) | ||
Net changes in assets and liabilities affecting operating activities: | ||||
Accounts receivable | (5,243,314) | (1,943,290) | ||
Inventories, net | 2,242,616 | 2,408,397 | ||
Other current assets and other assets | (231,829) | 189,112 | ||
Operating lease liabilities | (836,100) | 1,784,089 | ||
Accounts payable and other current liabilities | 6,709,196 | (991,359) | ||
Other long-term liabilities | (477,642) | (153,771) | ||
Net cash provided by (used in) operating activities | 4,932,522 | (612,186) | ||
Cash flows from investing activities: | ||||
Additions to property and equipment | (97,903) | (66,461) | ||
Additions to intangible assets | (84,402) | (113,253) | ||
Net investment in manufacturing | (2,477,192) | — | ||
Other investment | (2,000,000) | — | ||
Increase in cash surrender value of life insurance policies | (47,000) | — | ||
Life insurance policy proceeds received | — | 237,556 | ||
Net cash provided by (used in) investing activities | (4,706,497) | 57,842 | ||
Cash flows from financing activities: | ||||
Borrowings on line of credit | — | 38,488,920 | ||
Payments on line of credit | (10,035,437) | (35,996,894) | ||
Proceeds from ATM offering, net | 5,266,334 | — | ||
Payments made in connection with repurchase of common shares | (263,478) | (579,049) | ||
Cash settlement of contingent consideration | (1,712,935) | (1,716,073) | ||
Net cash provided by (used in) financing activities | (6,745,516) | 196,904 | ||
Net decrease in cash and cash equivalents | (6,519,491) | (357,440) | ||
Cash and cash equivalents, beginning of year | 17,964,184 | 18,321,624 | ||
Cash and cash equivalents, end of year | $ 11,444,693 | $ 17,964,184 | ||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Reconciliation of Net Income (Loss) Attributable to Common Shareholders to Adjusted Earnings (Loss) and (Unaudited) | ||||||||
Three months ended | Three months ended | |||||||
2025 | 2025 | 2024 | 2024 | |||||
Earnings | Earnings per | Earnings | Earnings per | |||||
Net loss attributable to common shareholders | $ (1,411,692) | $ (0.09) | $ (1,903,814) | $ (0.14) | ||||
Less: Net loss (income) at subsidiary attributable to | 16,950 | — | (2,177) | — | ||||
Net loss | (1,428,642) | (0.09) | (1,901,637) | (0.14) | ||||
Adjustments to net loss | ||||||||
Income tax benefit | 23,245 | — | (56,996) | — | ||||
Depreciation and amortization | 1,041,895 | 0.07 | 1,496,394 | 0.11 | ||||
Share-based compensation (a) | 172,160 | 0.01 | 74,812 | 0.01 | ||||
Interest income | (91,967) | (0.01) | (106,667) | (0.01) | ||||
Interest expense | 112,942 | 0.01 | 223,261 | 0.02 | ||||
Adjusted Earnings (loss) and Adjusted Diluted | $ (170,367) | $ (0.01) | $ (270,833) | $ (0.02) | ||||
Diluted weighted-average common shares outstanding: | 14,956,627 | 13,971,228 | ||||||
Additional Information: | ||||||||
Reduction in the carrying amount of right-of-use assets (b) | $ 285,184 | $ 0.02 | $ 285,184 | $ 0.02 | ||||
Year ended December 31, | Year ended December 31, | |||||||
2025 | 2025 | 2024 | 2024 | |||||
Earnings | Earnings per | Earnings | Earnings per | |||||
Net loss attributable to common shareholders | $ (2,836,128) | $ (0.19) | $ (6,479,770) | $ (0.46) | ||||
Less: Net loss (income) at subsidiary attributable to | 28,583 | — | (36,055) | — | ||||
Net loss | (2,864,711) | (0.19) | (6,443,715) | (0.46) | ||||
Adjustments to net loss | ||||||||
Income tax (benefit) expense | 40,256 | — | (22,669) | $ — | ||||
Depreciation and amortization | 4,145,201 | 0.27 | 4,902,560 | $ 0.35 | ||||
Share-based compensation (a) | 408,320 | 0.03 | 301,895 | $ 0.02 | ||||
Interest income | (476,748) | (0.03) | (334,444) | $ (0.02) | ||||
Interest expense | 495,990 | 0.03 | 605,508 | $ 0.04 | ||||
Adjusted Earnings (loss) and Adjusted Diluted | $ 1,748,308 | $ 0.11 | $ (990,865) | $ (0.07) | ||||
Diluted weighted-average common shares outstanding: | 15,245,309 | 14,060,272 | ||||||
Additional Information: | ||||||||
Reduction in the carrying amount of right-of-use assets (b) | $ 1,140,738 | $ 0.07 | $ 1,140,738 | $ 0.08 | ||||
The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.
Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
The Company defines these supplemental financial measures as follows:
- Adjusted Earnings: Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense.
(a) Represents the share-based compensation of
(b) Represents the straight line reduction in carrying value of right-of-use assets.
- Adjusted Diluted Earnings Per Share: Adjusted loss divided by diluted weighted-average common shares outstanding.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025-revenue-growth-302703089.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
What were Cumberland (CPIX) fourth quarter 2025 revenues and growth rate?
How much revenue did Cumberland (CPIX) generate in full-year 2025?
What did Cumberland (CPIX) report for 2025 net income and adjusted earnings?
What clinical progress did Cumberland (CPIX) announce for ifetroban in DMD?
What commercial and reimbursement milestones did Cumberland (CPIX) achieve in 2025?
